Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 58

1.

A multi-factorial genetic model for prognostic assessment of high risk melanoma patients receiving adjuvant interferon.

Wang E, Zhao Y, Monaco A, Uccellini L, Kirkwood JM, Spyropoulou-Vlachou M, Panelli MC, Marincola FM, Gogas H.

PLoS One. 2012;7(7):e40805. doi: 10.1371/journal.pone.0040805. Epub 2012 Jul 24.

2.

Concomitant detection of IFNα signature and activated monocyte/dendritic cell precursors in the peripheral blood of IFNα-treated subjects at early times after repeated local cytokine treatments.

Aricò E, Castiello L, Urbani F, Rizza P, Panelli MC, Wang E, Marincola FM, Belardelli F.

J Transl Med. 2011 May 17;9:67. doi: 10.1186/1479-5876-9-67.

3.

Microrna profiling analysis of differences between the melanoma of young adults and older adults.

Jukic DM, Rao UN, Kelly L, Skaf JS, Drogowski LM, Kirkwood JM, Panelli MC.

J Transl Med. 2010 Mar 19;8:27. doi: 10.1186/1479-5876-8-27.

4.

Serum vascular endothelial growth factor and fibronectin predict clinical response to high-dose interleukin-2 therapy.

Sabatino M, Kim-Schulze S, Panelli MC, Stroncek D, Wang E, Taback B, Kim DW, Deraffele G, Pos Z, Marincola FM, Kaufman HL.

J Clin Oncol. 2009 Jun 1;27(16):2645-52. doi: 10.1200/JCO.2008.19.1106. Epub 2009 Apr 13.

5.

Next generation of immunotherapy for melanoma.

Kirkwood JM, Tarhini AA, Panelli MC, Moschos SJ, Zarour HM, Butterfield LH, Gogas HJ.

J Clin Oncol. 2008 Jul 10;26(20):3445-55. doi: 10.1200/JCO.2007.14.6423. Review.

PMID:
18612161
6.

GM-CSF/IL-3/IL-5 receptor common beta chain (CD131) expression as a biomarker of antigen-stimulated CD8+ T cells.

Selleri S, Deola S, Pos Z, Jin P, Worschech A, Slezak SL, Rumio C, Panelli MC, Maric D, Stroncek DF, Wang E, Marincola FM.

J Transl Med. 2008 Apr 15;6:17. doi: 10.1186/1479-5876-6-17.

7.

Helper B cells promote cytotoxic T cell survival and proliferation independently of antigen presentation through CD27/CD70 interactions.

Deola S, Panelli MC, Maric D, Selleri S, Dmitrieva NI, Voss CY, Klein H, Stroncek D, Wang E, Marincola FM.

J Immunol. 2008 Feb 1;180(3):1362-72.

8.

Adjuvant therapy with high-dose interferon alpha 2b in patients with high-risk stage IIB/III melanoma.

Kirkwood JM, Tarhini AA, Moschos SJ, Panelli MC.

Nat Clin Pract Oncol. 2008 Jan;5(1):2-3. Epub 2007 Nov 13. No abstract available.

PMID:
18030300
9.

Gene expression profiling of cutaneous wound healing.

Deonarine K, Panelli MC, Stashower ME, Jin P, Smith K, Slade HB, Norwood C, Wang E, Marincola FM, Stroncek DF.

J Transl Med. 2007 Feb 21;5:11.

10.

Sequential gene profiling of basal cell carcinomas treated with imiquimod in a placebo-controlled study defines the requirements for tissue rejection.

Panelli MC, Stashower ME, Slade HB, Smith K, Norwood C, Abati A, Fetsch P, Filie A, Walters SA, Astry C, Aricó E, Zhao Y, Selleri S, Wang E, Marincola FM.

Genome Biol. 2007;8(1):R8.

11.

Comprehensive epitope mapping of the Epstein-Barr virus latent membrane protein-2 in normal, non tumor-bearing individuals.

Provenzano M, Selleri S, Jin P, Wang E, Werden R, Slezak S, Adams SD, Panelli MC, Leitman SF, Stroncek DF, Marincola FM.

Cancer Immunol Immunother. 2007 Jul;56(7):1047-63. Epub 2006 Nov 24.

PMID:
17124584
12.

Comparison of proteomic profiles of serum, plasma, and modified media supplements used for cell culture and expansion.

Ayache S, Panelli MC, Byrne KM, Slezak S, Leitman SF, Marincola FM, Stroncek DF.

J Transl Med. 2006 Oct 4;4:40.

13.

MHC-peptide specificity and T-cell epitope mapping: where immunotherapy starts.

Provenzano M, Panelli MC, Mocellin S, Bracci L, Sais G, Stroncek DF, Spagnoli GC, Marincola FM.

Trends Mol Med. 2006 Oct;12(10):465-72. Epub 2006 Sep 7.

PMID:
16962375
14.

Molecular signatures induced by interleukin-2 on peripheral blood mononuclear cells and T cell subsets.

Jin P, Wang E, Provenzano M, Deola S, Selleri S, Ren J, Voiculescu S, Stroncek D, Panelli MC, Marincola FM.

J Transl Med. 2006 Jun 28;4:26.

15.

Common cancer biomarkers.

Basil CF, Zhao Y, Zavaglia K, Jin P, Panelli MC, Voiculescu S, Mandruzzato S, Lee HM, Seliger B, Freedman RS, Taylor PR, Hu N, Zanovello P, Marincola FM, Wang E.

Cancer Res. 2006 Mar 15;66(6):2953-61.

16.

Detection of human MCP-4/CCL13 isoforms by SELDI immunoaffinity capture.

Rossi L, Moharram R, Martin BM, White RL, Panelli MC.

J Transl Med. 2006 Jan 24;4:5.

17.

Inflammatory protein profile during systemic high dose interleukin-2 administration.

Rossi L, Martin BM, Hortin GL, White RL, Foster M, Moharram R, Stroncek D, Wang E, Marincola FM, Panelli MC.

Proteomics. 2006 Jan;6(2):709-20.

PMID:
16342236
18.

A global approach to tumor immunology.

Wang E, Panelli MC, Monsurró V, Marincola FM.

Cell Mol Immunol. 2004 Aug;1(4):256-65. Review.

19.

Proteomic signature of myeloproliferation and neutrophilia: analysis of serum and plasma from healthy subjects given granulocyte colony-stimulating factor.

Stroncek D, Slezak S, Khuu H, Basil C, Tisdale J, Leitman SF, Marincola FM, Panelli MC.

Exp Hematol. 2005 Oct;33(10):1109-17.

PMID:
16219533
20.

Delayed polarization of mononuclear phagocyte transcriptional program by type I interferon isoforms.

Stroncek DF, Basil C, Nagorsen D, Deola S, Aricó E, Smith K, Wang E, Marincola FM, Panelli MC.

J Transl Med. 2005 Jun 13;3:24.

Supplemental Content

Loading ...
Support Center